Screener
Axsome Therapeutics AXSM Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 184,996 | 120,787 |
| Loss in fair value of contingent consideration | 590 | 1,512 |
| Intangible asset amortization | 1,572 | 1,572 |
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total costs & expenses?
- Axsome Therapeutics (AXSM) reported total costs & expenses of $254.56M in Q1 2026.
- How has Axsome Therapeutics's total costs & expenses changed year-over-year?
- Axsome Therapeutics's total costs & expenses increased by 42.7% year-over-year, from $178.45M to $254.56M.
- What is the long-term trend for Axsome Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Axsome Therapeutics's total costs & expenses has grown at a 59.4% compound annual growth rate (CAGR), from $124.71M to $805.26M.
- What does total costs & expenses mean?
- Total costs and expenses represent the aggregate of all operating and non-operating costs incurred by the company during a reporting period. This includes cost of revenue, R&D, SG&A, and other operational charges necessary to sustain the business.
Ask your AI about Axsome Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude